Keywords
Immunosuppressive
Tacrolimus
Mycophenolate mofetil
Valganciclovir
How to Cite
Abstract
Introduction: Leukopenia, particularly neutropenia, is a frequent hematological complication in kidney transplant recipients. It is most often related to immunosuppressive and prophylactic agents. These drugs are essential for preventing graft rejection and infection. However, they may induce myelosuppression. This leads to increased infection risk and often requires therapy modification.
Materials and Methods: We conducted a narrative review of the literature by searching PubMed, Embase, and Scopus for studies published between January 2010 and June 2024. Search terms included “leukopenia,” “neutropenia,” “drug-induced,” “kidney transplantation,” “mycophenolate,” “valganciclovir,” “tacrolimus,” “cotrimoxazole,” and “myelosuppression.” Eligible studies involved adult kidney transplant recipients and reported drug-induced leukopenia.
Results: Eight key studies were identified. Mycophenolate mofetil, valganciclovir, and trimethoprim-sulfamethoxazole were the most frequent causative agents. Tacrolimus was occasionally implicated. Reported incidence of leukopenia ranged from 19% to 83% during the first post-transplant year. Neutropenia occurred in up to 48% of patients. Risk factors included CMV D+/R− serostatus, combination therapy, and higher drug dosages. To illustrate clinical complexity, we present a case of a 36-year-old renal transplant recipient. He developed severe leukopenia and neutropenia two months post-transplant. White blood cell counts normalized following therapy adjustment and G-CSF administration, without subsequent rejection or infection.
Conclusion: Drug-induced leukopenia is a common complication after kidney transplantation. It is seen particularly with mycophenolate and valganciclovir, and less often with tacrolimus. Early detection, individualized dose adjustment, and supportive therapies are essential. These measures balance infection prevention with adequate immunosuppression. Standardized management guidelines are lacking, highlighting the need for prospective studies.
References
Gujral, N., Freeman, H. J., & Thomson, A. B. (2012). Celiac disease: prevalence, diagnosis, pathogenesis, and treatment. World journal of gastroenterology, 18(42), 6036–6059. https://doi.org/10.3748/wjg.v18.i42.6036
Paya, C., Humar, A., Dominguez, E., Washburn, K., Blumberg, E., Alexander, B., Freeman, R., Heaton, N., Pescovitz, M. D., & Valganciclovir Solid Organ Transplant Study Group (2004). Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 4(4), 611–620. https://doi.org/10.1111/j.1600-6143.2004.00382.x
Liang X, Famure O, Li Y, Kim SJ. Incidence and Risk Factors for Leukopenia in Kidney Transplant Recipients Receiving Valganciclovir for Cytomegalovirus Prophylaxis. Progress in Transplantation. 2018;28(2):124-133. doi:10.1177/1526924818765798
Rostaing, L., Jouve, T., Terrec, F., Malvezzi, P., & Noble, J. (2023). Adverse Drug Events after Kidney Transplantation. Journal of personalized medicine, 13(12), 1706. https://doi.org/10.3390/jpm13121706
Khalil K, Shapiro R, Jordan ML. Hematologic toxicities after renal transplantation: a comprehensive review. Transplant Rev (Orlando). 2018;32(1):58–67.
Rios JP, Mead LC. Tacrolimus-induced leukopenia: a case report and review of the literature. Clin Transplant. 2024;38(1):e14792.
Raval A, Patel H, Gill J. Drug-induced neutropenia in kidney transplantation: a systematic review. Nephrol Dial Transplant. 2022;37(6):1094–103.
De Rycke, A., Dierickx, D., & Kuypers, D. R. (2011). Tacrolimus-induced neutropenia in renal transplant recipients. Clinical journal of the American Society of Nephrology: CJASN, 6(3), 690–694. https://doi.org/10.2215/CJN.07320810
Zafrani, L., Truffaut, L., Kreis, H., Etienne, D., Rafat, C., Lechaton, S., Anglicheau, D., Zuber, J., Ciroldi, M., Thervet, E., Snanoudj, R., Mamzer, M. F., Martinez, F., Timsit, M. O., Bergougnoux, L., & Legendre, C. (2009). Incidence, risk factors, and clinical consequences of neutropenia following kidney transplantation: a retrospective study. American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 9(8), 1816–1825. https://doi.org/10.1111/j.1600-6143.2009.02699.x
Datrino, L. N., Boccuzzi, M. L., Silva, R. M., Castilho, P. H. B. T., Riva, W. J., Rocha, J. S., & Tustumi, F. (2024). Safety and Efficacy of Mycophenolate Mofetil Associated With Tacrolimus for Kidney-pancreas and Kidney Transplantation: A Systematic Review and Meta-Analysis of Randomized Studies. Transplantation proceedings, 56(5), 1066–1076. https://doi.org/10.1016/j.transproceed.2024.05.014
Lee, A. Y., Jeong, J., Heo, K. N., Park, S., Ah, Y. M., Han, J. M., Lee, J. Y., & Min, S. I. (2025). Complications Associated with Immunosuppressive Agents in Solid Organ Transplant Recipients: A Nationwide Analysis. Journal of Clinical Medicine, 14(10), 3602. https://doi.org/10.3390/jcm14103602
Dogjani, A., Vassiliu, P., Georgiou, C., et al. (2025). The 9th Albanian Congress of Trauma and Emergency Surgery. Albanian Journal of Trauma and Emergency Surgery, 9(2.9), 1-159. https://doi.org/10.32391/ajtes.v9i2.9.508